Login
$CTNM
$9.67 -$0.19 (1.93%) Live

Who owns Contineum?

Institutions own, across all of Contineum's classes · 13F as of Q2 2026
77.6%
of the economics
86.2%
of the votes
Top 10 holders, by whole-company stake
Holder CTNM Economics Votes
MONTANOVA CAPITAL, LLC 2.8M 7.24% 8.04%
Jupiter Topco LLC 2.7M 6.96% 7.74%

Sign up to see all 10.

Top 10 together 44.6% of the economics · 49.6% of the votes
By class
Class Shares outstanding Held by institutions Votes a share Economics a share
CTNM 35.4M 86.2% 1 vote 1
Class B 3.9M none filed no vote 1

SEC filing ctnm-20251231.htm: The dual class structure of our Class A and Class B common stock may limit your ability to influence corporate matters. Holders of our Class A common stock are entitled to one vote per share, while holders of our Class B common stock are not entitled to any votes. Nonetheless, each share of our Class B common stock may be converted at any time into one share of our Class A common stock at the o...

SEC filing ctnm-20260430.htm: You have received these proxy materials because the Board of Directors (our “Board” or the “Board of Directors”) of Contineum Therapeutics, Inc. (“we”, “us,” “our,” the “Company” or “Contineum”) is soliciting your proxy to vote at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). This proxy statement, along with the accompanying Notice of Annual Meeting of Stockholders, summarizes...

How is ownership changing?

Institutions, last 8 quarters

A trend across this company's share classes isn't available yet: each quarter's 13F filings add up shares of classes that differ in economics and votes.

Biggest buyers in Q2 2026
  • Jupiter Topco LLC NEW +2.7M
  • BlackRock, Inc. +1.4M

Sign up to see all 5.

Biggest sellers in Q2 2026
  • Janus Henderson Group PLC SOLD OUT −2.7M
  • Baker Bros. Advisors LP SOLD OUT −1.4M

Sign up to see all 5.

Who is planning to sell?

Notices of proposed sale, last 12 months
$2.16M
19 notices from 4 people
Arranged in advance
100%
of the value is under a 10b5-1 plan
Under a 10b5-1 plan No plan
$0$400.6K$801.1KDec 2025: $185.6K under a 10b5-1 planDecJan 2026: $47.5K under a 10b5-1 planJanFeb 2026: $430.9K under a 10b5-1 planFebMarApr 2026: $12.3K under a 10b5-1 planAprMay 2026: $53.5K under a 10b5-1 planMayJun 2026: $801.1K under a 10b5-1 planJunJul 2026: $192.4K under a 10b5-1 planJulAug 2026: $186.2K under a 10b5-1 planAugSep 2026: $196.4K under a 10b5-1 planSepOct 2026: $56.0K under a 10b5-1 planOctNov
Largest proposed sellers
  • Daniel Lorrain Officer 10b5-1 $946K
  • Daniel Lorrain Officer 10b5-1 $533K

Sign up to see all 4.

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2023–FY2025
+715.8%
+185.62% a year
Each share's claim on the business
−87.7%
shrank without buying or selling a share
Spent on buybacks vs paid in stock
— vs $19.1M
over 3 fiscal years
Diluted shares, split-adjusted
3.3M15.6M28.0M2023: 3.4M shares'232024: 19.4M shares'242025: 27.7M shares'25
Buybacks Stock-based comp
$0$5.0M$10.0M2023 buybacks: $02023 stock comp: $2.2M'232024 buybacks: $02024 stock comp: $6.8M'242025 buybacks: $02025 stock comp: $10.0M'25

How patient are the owners?

Institutional shares by how long they've been held
5+ years0% 3–5 years0% 1–3 years64% Under 1 year36%
Quarterly turnover
25.8%
of institutional shares changed hands
Top 10 managers, median time held
2 years

Super Investors

Investment managers reporting Contineum on Form 13F
MC
Montanova Capital, LLC
Shares
2.8M
% of company
—
Change vs last qtr
Unchanged
Held since
2024
JH
Janus Henderson Group PLC
Shares
—
% of company
—
Change vs last qtr
SOLD OUT
Held since
—

28 more super investors behind a free account

See every manager holding Contineum Therapeutics, Inc., how their position has changed, and how long they've held it.

Sign up free

Institutional Funds

Mutual funds and ETFs reporting Contineum on Form N-PORT
VT
Position value
$16.1M
% of company
—
% of the fund
0.00%
As of
June 30, 2026
IR
iShares Trust
Position value
$10.6M
% of company
—
% of the fund
0.01%
As of
June 30, 2026

23 more funds behind a free account

See every fund holding Contineum Therapeutics, Inc. and how much of the fund the position is.

Sign up free

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
LD
Lorrain Daniel S.
Insider
Shares
145.3K
% of company
—
Change vs last qtr
—
Held since
—
SC
Stengone Carmine N.
Insider
Shares
17.2K
% of company
—
Change vs last qtr
—
Held since
—

1 more holders behind a free account

See every insider and 5%+ holder of Contineum Therapeutics, Inc..

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support